FactaeThe Factual News

Novartis suffers setback in heart disease prevention

Swiss pharmaceutical group Novartis seeks a successor to its blockbuster Entresto.

Published 1j3 sources✓ ConfirmedNotableupdated 6h
Lire en français
≈ 13s

The fact

Results in heart disease prevention are disappointing.

Novartis may shift focus to other therapeutic areas.

3 sources — click a link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Suisse · © OpenStreetMap, OpenMapTiles, OpenFreeMapWorld map →
Follow topic →
Auto-synthesis from 3 media sources · identified on September 7, 2026
← Back to home
Discover

Read more

All monde →
marches

Novartis: experimental heart drug fails key trial

3j · 1 sourcemonde

Novartis revives growth despite losing patents on Entresto

7sem · 1 sourcemarches9 %

Novartis shares plummet after two consecutive clinical failures

9h · 1 sourcemarches

Novartis highlighted at the 2026 European Society of Cardiology congress

2sem · 1 sourcemarches

Novartis halts clinical trials after deaths in cell therapy

1sem · 1 sourcemarches

Novartis resists generic competition with rising profits

7sem · 1 source